Akèy › Leksemi biphenotipik egi
Etid klinik pou Leksemi biphenotipik egi ap rekrite nan Etazini
37 etid pou Leksemi biphenotipik egi ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Seattle, WA15 etid
- Houston, TX11 etid
- New York City, NY10 etid
- Atlanta, GA9 etid
- Durham, NC8 etid
- Chicago, IL7 etid
- Memphis, TN7 etid
- Aurora, CO6 etid
- Dallas, TX6 etid
- Philadelphia, PA6 etid
- Baldwin Park, CA6 etid
- Los Angeles, CA6 etid
- Portland, OR6 etid
- Charlotte, NC6 etid
- Boston, MA5 etid
- San Francisco, CA5 etid
- Fort Worth, TX5 etid
- Cincinnati, OH5 etid
- San Diego, CA5 etid
- Tampa, FL5 etid
- Clifton, NJ5 etid
- Nashville, TN5 etid
- Greenburgh, NY5 etid
- Columbus, OH5 etid
- Minneapolis, MN5 etid
- Mountain View, CA4 etid
- Kansas City, MO4 etid
- Gainesville, FL4 etid
- Denver, CO4 etid
- Jacksonville, FL4 etid
- Louisville, KY4 etid
- Akron, OH4 etid
- Omaha, NE4 etid
- Edison, NJ4 etid
- Washington, DC4 etid
- Ann Arbor, MI4 etid
- St. Louis, MO4 etid
- Baltimore, MD4 etid
- Milwaukee, WI4 etid
- Indianapolis, IN4 etid
Pa eta
- Alabama3 etid
- Alaska3 etid
- Arizona3 etid
- Arkansas3 etid
- Ayiti3 etid
- Colorado8 etid
- Connecticut3 etid
- Delaware3 etid
- Distrik Columbia4 etid
- Florid9 etid
- Georgia9 etid
- Idaho3 etid
- Illinois7 etid
- Indiana4 etid
- Iowa4 etid
- Kalifòni15 etid
- Kentucky4 etid
- Lwizyàn4 etid
- Main3 etid
- Maryland4 etid
- Massachusetts5 etid
- Michigan4 etid
- Minnesota6 etid
- Mississippi3 etid
- Missouri5 etid
- Nebraska4 etid
- Nevada3 etid
- New Hampshire3 etid
- New Jersey6 etid
- New York11 etid
- North Carolina11 etid
- North Dakota3 etid
- Ohio8 etid
- Oklahoma5 etid
- Oregon6 etid
- Pennsylvania6 etid
- Rhode Island3 etid
- South Carolina3 etid
- South Dakota3 etid
- Tennessee10 etid
- Texas13 etid
- Utah3 etid
- Virginia3 etid
- Washington15 etid
- West Virginia3 etid
- Wisconsin5 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Ap rekriteFaz 1
Laj 12 a 78 · Tout sèks · Mizajou Sep 29, 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07094750CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04375631A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Ap rekriteFaz 1/2
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT03683433Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Ap rekriteFaz 1/2Volontè an sante akeyi
Jiska laj 50 · Tout sèks · Mizajou Sep 1, 2026 · NCT05322850Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Ap rekriteFaz 2
Laj 1 a 18 · Tout sèks · Mizajou Aug 10, 2026 · NCT06390319Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06177067Personalized NK Cell Therapy in CBT
Ap rekriteFaz 2
Laj 15 a 80 · Tout sèks · Mizajou Jul 30, 2026 · NCT02727803Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Ap rekriteFaz 2
6 Months – 65 Years · Tout sèks · Mizajou Jul 22, 2026 · NCT06013423Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT07046078Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
Ap rekriteFaz 4
Laj 1 a 18 · Tout sèks · Mizajou Jul 14, 2026 · NCT06289673Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07216443Allo HSCT Using RIC and PTCy for Hematological Diseases
Ap rekriteFaz 2
Jiska laj 75 · Tout sèks · Mizajou Jul 6, 2026 · NCT05805605Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Jun 23, 2026 · NCT06551584211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03128034211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Jun 22, 2026 · NCT03670966A Study of Revumenib and Mezigdomide in People With Leukemia
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT07356154Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT04047641Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Ap rekriteFaz 2Volontè an sante akeyi
6 Months · Tout sèks · Mizajou May 29, 2026 · NCT04195633Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.